



## **Comparative evaluation and user experience with the Alinity m HIV-1 assay in Europe, South Africa and Australia**

ASLM2021 Satellite Session

### **Sponsor**

Abbott

### **Date and Time**

16 November 2021, 8AM-9AM GMT

### **Summary**

It has been estimated that there are 37.9 million individuals living with HIV-1 worldwide, with 24.5 million receiving antiretroviral treatments. The Joint United Nations Program on HIV/AIDS (UNAIDS) organization announced the 90-90-90 program which aims to close the gap between HIV-1 diagnosis, treatment and viral suppression. In order to address the goals of this program, early diagnosis and accurate HIV-1 RNA viral load monitoring is critical. The symposium details the findings of an international multicenter study comparing the performance of the Alinity m HIV-1 Assay to four commercially available HIV-1 viral load assays. The study findings and insights are even more relevant today as countries get their HIV viral load programs back on track, post COVID, and progress towards the 95-95-95 targets.

### **Learning Objectives**

1. Understand how the Alinity m HIV-1 assay could add value in lab strengthening efforts toward HIV viral load scale up
2. Lab workflow improvements can improve turn around time
3. How stat functionality can add value to the molecular lab

### **Target Audience**

Ministry of Health, Lab directors, Technical officers, Program managers, medical technicians, implementation partners, funders,

### **Speakers**

Dr Birgit Reinhardt (Abbott)

Dr Leana Maree (Lancet Laboratories)